Barrington Research Reaffirms Outperform Rating for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities research analysts at Barrington Research in a report issued on Friday,Benzinga reports. They presently have a $95.00 price target on the medical instruments supplier's stock. Barrington Research's target price indicates a potential upside of 25.74% from the company's previous close.

Other equities research analysts have also recently issued research reports about the company. Raymond James Financial reiterated a "strong-buy" rating and set a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Needham & Company LLC dropped their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. JMP Securities restated a "market outperform" rating and issued a $100.00 price target on shares of Haemonetics in a research note on Tuesday, May 20th. Finally, Robert W. Baird started coverage on Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $97.30.

Haemonetics Stock Down 3.4%

NYSE HAE traded down $2.62 during trading on Friday, hitting $75.55. The stock had a trading volume of 660,605 shares, compared to its average volume of 675,269. The company has a market capitalization of $3.63 billion, a PE ratio of 22.82, a P/E/G ratio of 1.27 and a beta of 0.39. The company's 50-day moving average price is $70.50 and its two-hundred day moving average price is $68.06. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62. Haemonetics has a 12 month low of $55.30 and a 12 month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The firm had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. During the same quarter in the previous year, the business posted $0.90 EPS. The business's quarterly revenue was down 3.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Haemonetics will post 4.55 EPS for the current year.

Institutional Trading of Haemonetics

Several hedge funds have recently made changes to their positions in HAE. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics during the 4th quarter valued at $25,000. Quarry LP raised its stake in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares during the period. UMB Bank n.a. raised its stake in shares of Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock valued at $50,000 after purchasing an additional 320 shares during the period. Covestor Ltd raised its stake in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares during the period. Finally, Whittier Trust Co. bought a new stake in shares of Haemonetics during the 4th quarter valued at $62,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.